Gabriel - Ioan Prada

Prof. Dr. Gabriel - Ioan Prada

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Rima ObeidRima Obeid
Rima Obeid
Emmanuel AndrèsEmmanuel Andrès
Emmanuel Andrès
RČRichard Češka
Richard Češka
BHBabak Hooshmand
Babak Hooshmand
RGRosa-Maria Guéant-Rodriguez
Rosa-Maria Guéant-Rodriguez
TGThe Vitamin B12 Consensus Panelists Group
The Vitamin B12 Consensus Panelists Group
Background/Objectives: Vitamin B12 deficiency can cause variable symptoms, which may be irreversible if not diagnosed and treated in a timely manner. We aimed to develop a widely accepted expert consensus to guide the practice of diagnosing and treating B12 deficiency. Methods: We conducted a scoping review of the literature published in PubMed since January 2003. Data were used to design a two-round Delphi survey to study the level of consensus among 42 experts. Results: The panelists agreed on the need for educational and organizational changes in the current medical practices for diagnosing and treating B12 deficiency. Recognition of clinical symptoms should receive the highest priority in establishing the diagnosis. There is agreement that the serum B12 concentration is useful as a screening marker and methylmalonic acid or homocysteine can support the diagnosis. Patient lifestyle, disease history, and medications can provide clues to the cause of B12 deficiency. Regardless of the cause of the deficiency, initial treatment with parenteral B12 was regarded as the first choice for patients with acute and severe manifestations of B12 deficiency. The use of high-dose oral B12 at different frequencies may be considered for long-term treatment. Prophylactic B12 supplementation should be considered for specific high-risk groups. Conclusions: There is a consensus that clinical symptoms need to receive more attention in establishing the diagnosis of B12 deficiency. B12 laboratory markers can support the diagnosis. The severity of clinical symptoms, the causes of B12 deficiency, and the treatment goals govern decisions regarding the route and dose of B12 therapy.

1 December 2012 in Aging Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
DANIELA GRADINARUDANIELA GRADINARU
DANIELA GRADINARU
CBClaudia Borsa
Claudia Borsa
CICristina Ionescu
Cristina Ionescu
DMDenisa Margina
Denisa Margina
Gabriel - Ioan PradaGabriel - Ioan Prada
Gabriel - Ioan Prada
EJEugène Jansen
Eugène Jansen

Verified
Closed access
DANIELA GRADINARUDANIELA GRADINARU
DANIELA GRADINARU
CBClaudia Borsa
Claudia Borsa
CICristina Ionescu
Cristina Ionescu
Denisa MarginaDenisa Margina
Denisa Margina
Gabriel - Ioan PradaGabriel - Ioan Prada
Gabriel - Ioan Prada
EJEugene Jansen
Eugene Jansen

16 August 2021 in Journal of Ambient Intelligence and Humanized Computing
Verified
Journal Article
Open access
PDF file
Susanna SpinsanteSusanna Spinsante
Susanna Spinsante
APAngelica Poli
Angelica Poli
JBJordi Mongay Batalla
Jordi Mongay Batalla
PKPiotr Krawiec
Piotr Krawiec
CDCiprian Dobre
Ciprian Dobre
Horacio González-VélezHoracio González-Vélez
Horacio González-Vélez
One of the most important lifestyle risk factors for many chronic conditions in the older age, low physical activity has shown to have significant impact on the sustainability of national welfare in many developed countries. Technology-based assisted living solutions can effectively be used to enable older adults to optimise their health-related quality of life, as well as to promote an active and healthy longevity. This paper describes vINCI—an interdisciplinary research project to actively support assisted living for older adults via state-of-the-art assistive technologies—which seamlessly deploys an ambient intelligence environment to integrate wearable devices, networking, software, and personalised services. It entails clinical validation and feedback at home and residential care facilities via a cloud microservices platform. Underpinned by blockchain technologies, multiple wearable devices, apps, and cameras securely capture the anonymised facets of different life events, whilst machine learning models create individualised user profiles to analyse any decrease in the perceived health-related quality of life typically associated with old age. Two controlled pilots are being conducted with 80 participants at older adult facilities in Romania and Cyprus. By incorporating clinical validation and feedback from specialised practitioners, the vINCI technologies enable older adults not only to self-evaluate their physical activity level, but also to change their behaviours and lifestyle in the long-term.

9 April 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Rima ObeidRima Obeid
Rima Obeid
Emmanuel AndrèsEmmanuel Andrès
Emmanuel Andrès
RČRichard Češka
Richard Češka
BHBabak Hooshmand
Babak Hooshmand
RGRosa-Maria Guéant-Rodriguez
Rosa-Maria Guéant-Rodriguez
KRKarlheinz Reiners
Karlheinz Reiners
Background/Objectives: Vitamin B12 deficiency can cause variable symptoms, which may be irreversible if not diagnosed and treated in a timely manner. We aimed to develop a widely accepted expert consensus to guide the practice of diagnosing and treating B12 deficiency. Methods: We conducted a scoping review of the literature published in PubMed since January 2003. Data were used to design a two-round Delphi survey to study the level of consensus among 42 experts. Results: The panelists agreed on the need for educational and organizational changes in the current medical practices for diagnosing and treating B12 deficiency. Recognition of clinical symptoms should receive the highest priority in establishing the diagnosis. There is agreement that the serum B12 concentration is useful as a screening marker, whereas methylmalonic acid or homocysteine can support the diagnosis. Patient lifestyle, disease history and medications can provide clues to the cause of B12 deficiency. Regardless of the cause of the deficiency, initial treatment with parenteral B12 was regarded as the first choice for patients with acute and severe manifestations of B12 deficiency. The use of high-dose oral B12 at different frequencies may be considered for long-term treatment. Prophylactic B12 supplementation should be considered for specific high-risk groups. Conclusions: There is a consensus that clinical symptoms need to receive more attention in establishing a diagnosis. B12 laboratory markers can support the diagnosis. The severity of clinical symptoms, the causes of B12 deficiency and the treatment goals govern decisions regarding the route and dose of B12 therapy.

1 January 2021 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
EMElena Milanesi
Elena Milanesi
Gina MandaGina Manda
Gina Manda
MDMaria Dobre
Maria Dobre
ECElena Codrici
Elena Codrici
INIonela Victoria Neagoe
Ionela Victoria Neagoe
Antonio CuadradoaAntonio Cuadradoa
Antonio Cuadradoa
Purpose: Chronic low-grade inflammation and oxidative stress are present in most of the pathologic mechanisms underlying non-communicable diseases. Inflammation and redox biomarkers might therefore have a value in disease prognosis and therapy response. In this context, we performed a case-control study for assessing in whole blood the expression profile of inflammation and redox-related genes in elderly subjects with various comorbidities. Patients and Methods: In the blood of 130 elderly subjects with various pathologies (cardiovascular disease, hypertension, dyslipidemia including hypercholesterolemia, type 2 diabetes mellitus), kept under control by polyvalent disease-specific medication, we investigated by pathway-focused qRT-PCR a panel comprising 84 inflammation-related and 84 redox-related genes. Results: The study highlights a distinctive expression profile of genes critically involved in NF-kappa B-mediated inflammation and redox signaling in the blood of patients with cardiovascular disease, characterized by significant down-regulation of the genes NFKB2, NFKBIA, RELA, RELB, AKT1, IRF1, STAT1, CD40, LTA, TRAF2, PTGS1, ALOX12, DUOX1, DUOX2, MPO, GSR, TXNRD2, HSPA1A, MSRA, and PDLIM]. This gene expression profile defines the transcriptional status of blood leukocytes in stable disease under medication control, without discriminating between disease- and therapy-related changes. Conclusion: The study brings preliminary proof on a minimally invasive strategy for monitoring disease in patients with cardiovascular pathology, from the point of view of inflammation or redox dysregulation in whole blood.